Cargando…

Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report

BACKGROUND: Cabazitaxel (CBZ) chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) is believed to be palliative because the radiological response rate is low and a durable response is rare. Here, we describe a rare case of a patient with mCRPC who was treated with CBZ chemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosaka, Takeo, Hongo, Hiroshi, Oya, Mototsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558884/ https://www.ncbi.nlm.nih.gov/pubmed/31185946 http://dx.doi.org/10.1186/s12885-019-5782-2

Ejemplares similares

Analysis of cabazitaxel‐resistant mechanism in human castration‐resistant prostate cancer
por: Hongo, Hiroshi, et al.
Publicado: (2018)

Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer
por: Watanabe, Keitaro, et al.
Publicado: (2021)

Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Reactive oxygen species induction by cabazitaxel through inhibiting Sestrin-3 in castration resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2017)

No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2018)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations
por: Kamisawa, Ken, et al.
Publicado: (2022)

Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review
por: Masuda, Tsukasa, et al.
Publicado: (2022)

Complete Response to Bicalutamide Withdrawal Prolonged for Almost 2 Years in Patients With Metastatic Prostate Cancer()
por: Hongo, Hiroshi, et al.
Publicado: (2014)

Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel
por: Kosaka, Takeo, et al.
Publicado: (2018)

Cranial nerve palsy caused by metastasis to the skull base in patients with castration‐resistant prostate cancer: Three case reports
por: Yasumizu, Yota, et al.
Publicado: (2021)

Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan
por: Kosaka, Takeo, et al.
Publicado: (2019)

PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer
por: Yasumizu, Yota, et al.
Publicado: (2018)

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
por: Komori, Takahiro, et al.
Publicado: (2022)

A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report
por: Iwasawa, Tomohiro, et al.
Publicado: (2022)

Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report
por: Hongo, Hiroshi, et al.
Publicado: (2020)

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
por: Mofid, Bahram, et al.
Publicado: (2015)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

The first Japanese case of intraductal cancer of the prostate with checkpoint kinase 2 mutation
por: Hongo, Hiroshi, et al.
Publicado: (2022)

Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity
por: Kosaka, Takeo, et al.
Publicado: (2013)

Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
por: Baba, Yuto, et al.
Publicado: (2022)

Safety and efficacy of cabazitaxel in Japanese patients with castration-resistant prostate cancer
por: Yamamoto, Teppei, et al.
Publicado: (2020)

Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2011)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic Cancer
por: Mehdorn, Anne-Sophie, et al.
Publicado: (2022)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion
por: Shojo, Kazunori, et al.
Publicado: (2021)

First successful case of platinum‐based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations
por: Omura, Minami, et al.
Publicado: (2021)

Germline BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Brachytherapy seeds as a nidus for urethral stone formation: A case report
por: Kamisawa, Ken, et al.
Publicado: (2019)

A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation
por: Kosaka, Takeo, et al.
Publicado: (2019)

A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations
por: Kobayashi, Hiroaki, et al.
Publicado: (2021)

Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification
por: Daimon, Tatsuaki, et al.
Publicado: (2021)

Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
por: Colbourn, Donald
Publicado: (2012)

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Belderbos, Bodine P.S., et al.
Publicado: (2017)

The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Buonerba, Carlo, et al.
Publicado: (2017)

Vasohibin-1 expression as a biomarker of aggressive nature in ductal adenocarcinoma of the prostate: a retrospective cohort study at two centres in Japan
por: Kobayashi, Hiroaki, et al.
Publicado: (2021)

Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer
por: Takayama, Ken-ichi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tp8tpjqflnf0vfdpuqpic3fh8e